Estrella Immunopharma completes second dose cohort in STARLIGHT-1 trial

Estrella Immunopharma (ESLA) announced the completion of the second dose cohort in Phase I portion of its STARLIGHT-1 Phase I/II clinical trial of EB103, a CD19-redirected Artemis T-cell therapy to treat patients with Advanced B-Cell Non-Hodgkin’s Lymphomas. The study has achieved a 100% complete response rate at Month 1 in all evaluable patients treated in the second dose cohort. All patients treated are considered high-risk group who are not suitable to receive commercial CD19 products, including one with Central Nervous System lymphoma. No treatment-related serious adverse events were reported during this study phase. Following the completion of this dose cohort, a Data and Safety Monitoring Board will review the cumulative study data to evaluate the safety and efficacy of EB103, and to determine the Recommended Phase II Dose for the expansion phase. The DSMB is an independent group of experts that assesses the study’s progress and makes recommendations to the trial’s sponsor.